Biomerica (BMRA) Stock Price

Biomerica Price

NASDAQ·CLOSED
1.58USD-0.04 (-2.50 %)
Market closed

Revenue at Biomerica has contracted by 1.6% per year over the past 19 years to 5.31 M USD. Earnings per share have grown at 10.7% per year over the last 7 years. For Biomerica, the net margin of -93.6% is up versus -103.4% a few years ago. The consensus 12-month price target for Biomerica is 13.26 USD, about 739.2% above where the stock trades today. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 6% above its 52-week low.

Biomerica stock price

Volume
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Biomerica over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Biomerica stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Biomerica's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Biomerica Stock Price History
DateBiomerica Price
8/14/20261.58 USD
8/13/20261.62 USD
8/12/20261.57 USD
8/11/20261.57 USD
8/10/20261.63 USD
8/7/20261.61 USD
8/6/20261.60 USD
8/5/20261.59 USD
8/4/20261.53 USD
8/3/20261.53 USD
7/31/20261.49 USD
7/30/20261.59 USD
7/29/20261.55 USD
7/27/20261.62 USD
7/23/20261.60 USD
7/22/20261.57 USD
7/21/20261.64 USD
7/20/20261.60 USD
7/17/20261.61 USD
7/16/20261.63 USD
7/15/20261.67 USD
7/14/20261.63 USD
7/13/20261.69 USD
7/10/20261.69 USD
7/9/20261.65 USD
7/8/20261.66 USD
7/7/20261.72 USD
7/6/20261.72 USD
7/2/20261.75 USD
7/1/20261.80 USD
6/30/20261.76 USD
6/29/20261.77 USD
6/26/20261.75 USD
6/25/20261.75 USD
6/24/20261.75 USD
6/23/20261.76 USD
6/22/20261.83 USD
6/18/20261.79 USD
6/17/20261.97 USD
6/16/20261.93 USD
6/15/20262.00 USD
6/12/20262.05 USD
6/11/20262.09 USD
6/10/20262.02 USD
6/9/20262.05 USD
6/8/20262.07 USD
6/5/20262.12 USD
6/4/20262.15 USD
6/3/20262.11 USD
6/2/20262.18 USD
6/1/20262.36 USD
5/29/20262.39 USD
5/28/20262.43 USD
5/27/20262.46 USD
5/26/20262.47 USD
5/22/20262.49 USD
5/21/20262.44 USD
5/20/20262.35 USD
5/19/20262.38 USD
5/18/20262.25 USD
5/15/20262.34 USD
5/14/20262.41 USD
5/13/20262.25 USD
5/12/20262.29 USD
5/11/20262.28 USD
5/8/20262.22 USD
5/7/20262.20 USD
5/6/20262.21 USD
5/5/20262.19 USD
5/4/20262.16 USD
5/1/20262.19 USD
4/30/20262.18 USD
4/29/20262.16 USD
4/28/20262.18 USD
4/27/20262.18 USD
4/24/20262.14 USD
4/23/20262.15 USD
4/22/20262.18 USD
4/21/20262.16 USD
4/20/20262.18 USD
4/17/20262.18 USD
4/16/20262.20 USD
4/15/20262.11 USD
4/14/20262.10 USD
4/13/20262.08 USD
4/10/20262.13 USD
4/9/20262.20 USD
4/8/20262.15 USD
4/7/20262.16 USD
4/6/20262.17 USD
4/2/20262.17 USD
4/1/20262.19 USD
3/31/20262.12 USD
3/30/20262.05 USD
3/27/20262.01 USD
3/26/20262.11 USD
3/25/20262.16 USD
3/24/20262.16 USD
3/23/20262.13 USD
3/20/20262.19 USD
3/19/20262.08 USD
3/18/20262.14 USD
3/17/20262.08 USD
3/16/20262.00 USD
3/13/20261.97 USD
3/12/20261.97 USD
3/11/20262.02 USD
3/10/20262.23 USD
3/9/20262.19 USD
3/6/20261.92 USD
3/5/20261.97 USD
3/4/20262.03 USD
3/3/20262.03 USD
3/2/20262.03 USD
2/27/20262.08 USD
2/26/20262.05 USD
2/25/20262.16 USD
2/24/20262.10 USD
2/23/20262.10 USD
2/20/20262.17 USD
2/19/20262.22 USD
2/18/20262.23 USD
2/17/20262.23 USD
2/13/20262.29 USD
2/12/20262.16 USD
2/11/20262.28 USD
2/10/20262.32 USD
2/9/20262.17 USD
2/6/20262.25 USD
2/5/20262.27 USD
2/4/20262.29 USD
2/3/20262.34 USD
2/2/20262.41 USD
1/30/20262.38 USD
1/29/20262.39 USD
1/28/20262.42 USD
1/27/20262.44 USD
1/26/20262.43 USD
1/23/20262.57 USD
1/22/20262.57 USD
1/21/20262.47 USD
1/20/20262.56 USD
1/16/20262.57 USD
1/15/20262.68 USD
1/14/20262.70 USD
1/13/20262.71 USD
1/12/20262.68 USD
1/9/20262.73 USD
1/8/20262.88 USD
1/7/20262.78 USD
1/6/20262.67 USD
1/5/20262.60 USD
1/2/20262.53 USD
12/31/20252.52 USD
12/30/20252.45 USD
12/29/20252.66 USD
12/26/20252.70 USD
12/24/20252.65 USD
12/23/20252.62 USD
12/22/20252.37 USD
12/19/20252.31 USD
12/18/20252.35 USD
12/17/20252.39 USD
12/16/20252.37 USD
12/15/20252.47 USD
12/12/20252.58 USD
12/11/20252.58 USD
12/10/20252.50 USD
12/9/20252.54 USD
12/8/20252.49 USD
12/5/20252.34 USD
12/4/20252.30 USD
12/3/20252.31 USD
12/2/20252.34 USD
12/1/20252.26 USD
11/28/20252.37 USD
11/26/20252.32 USD
11/25/20252.39 USD
11/24/20252.29 USD
11/21/20252.23 USD
11/20/20252.24 USD
11/19/20252.18 USD
11/18/20252.25 USD
11/17/20252.29 USD
11/14/20252.41 USD
11/13/20252.50 USD
11/12/20252.52 USD
11/11/20252.53 USD
11/10/20252.47 USD
11/7/20252.46 USD
11/6/20252.55 USD
11/5/20252.58 USD
11/4/20252.48 USD
11/3/20252.71 USD
10/31/20252.79 USD
10/30/20252.76 USD
10/29/20252.79 USD
10/28/20252.93 USD
10/27/20252.96 USD
10/24/20252.96 USD
10/23/20252.91 USD
10/22/20252.93 USD
10/21/20253.20 USD
10/20/20253.12 USD
10/17/20252.98 USD
10/16/20253.01 USD
10/15/20252.86 USD
10/14/20252.88 USD
10/13/20252.80 USD
10/10/20252.83 USD
10/9/20252.95 USD
10/8/20252.88 USD
10/7/20252.84 USD
10/6/20252.93 USD
10/3/20252.80 USD
10/2/20252.76 USD
10/1/20252.82 USD
9/30/20252.83 USD
9/29/20252.85 USD
9/26/20252.81 USD
9/25/20252.80 USD
9/24/20252.91 USD
9/23/20252.85 USD
9/22/20252.84 USD
9/19/20252.88 USD
9/18/20252.93 USD
9/17/20252.92 USD
9/16/20253.00 USD
9/15/20252.99 USD
9/12/20252.98 USD
9/11/20252.95 USD
9/10/20252.93 USD
9/9/20252.91 USD
9/8/20252.91 USD
9/5/20252.75 USD
9/4/20252.82 USD
9/3/20252.85 USD
9/2/20253.00 USD
8/29/20253.13 USD
8/28/20253.16 USD
8/27/20253.15 USD
8/26/20253.29 USD
8/25/20253.43 USD
8/22/20253.47 USD
8/21/20253.41 USD
8/20/20253.21 USD
8/19/20252.97 USD
8/18/20253.07 USD
Access this data via the Eulerpool API

Biomerica Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
5.20 M USD
-2.41 M USD
-2.39 M USD
Jan 1, 2020
6.69 M USD
-2.40 M USD
-2.34 M USD
Jan 1, 2021
7.20 M USD
-7.50 M USD
-7.45 M USD
Jan 1, 2022
18.87 M USD
-4.53 M USD
-4.53 M USD
Jan 1, 2023
5.34 M USD
-7.22 M USD
-7.14 M USD
Jan 1, 2024
5.42 M USD
-6.37 M USD
-5.98 M USD
Jan 1, 2025
5.31 M USD
-5.14 M USD
-4.97 M USD
Jan 1, 2026 (e)
74.24 M USD
31.46 M USD
7.36 M USD

Biomerica Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 16, 2026, 6:49 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2011201220132014201520162017201820192020202120222023202420252026e
4.006.006.005.004.005.005.005.005.006.007.0018.005.005.005.0074.00
-20.0050.00-16.67-20.0025.0020.0016.67157.14-72.221,380.00
25.0033.3333.3320.0025.0020.0040.0020.0020.0016.6728.5711.1140.0040.0040.0011.11
1.002.002.001.001.001.002.001.001.001.002.002.002.002.002.008.22
-1.00-2.00-2.00-7.00-4.00-7.00-6.00-5.0031.00
-20.00-40.00-33.33-100.00-22.22-140.00-120.00-100.0041.89
-1.00-1.00-2.00-2.00-7.00-4.00-7.00-5.00-4.007.00
100.00250.00-42.8675.00-28.57-20.00-275.00
6.927.397.287.557.598.198.529.069.8211.7612.5913.4616.8217.122.912.91
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Biomerica generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Biomerica retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Biomerica's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Biomerica has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Biomerica's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Biomerica stock margins

The Biomerica margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biomerica. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biomerica.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
24.84 %
-46.39 %
-46.01 %
Jan 1, 2020
26.62 %
-35.90 %
-34.95 %
Jan 1, 2021
5.09 %
-104.18 %
-103.43 %
Jan 1, 2022
15.78 %
-24.03 %
-24.01 %
Jan 1, 2023
8.35 %
-135.29 %
-133.73 %
Jan 1, 2024
11.28 %
-117.58 %
-110.40 %
Jan 1, 2025
9.38 %
-96.72 %
-93.64 %
Jan 1, 2026 (e)
9.38 %
42.37 %
9.92 %

Biomerica Stock Revenue, EBIT, Earnings per Share

The Biomerica earnings per share therefore indicates how much revenue Biomerica has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2019
0.53 USD
-0.25 USD
-0.24 USD
Jan 1, 2020
0.57 USD
-0.20 USD
-0.20 USD
Jan 1, 2021
0.57 USD
-0.60 USD
-0.59 USD
Jan 1, 2022
1.40 USD
-0.34 USD
-0.34 USD
Jan 1, 2023
0.32 USD
-0.43 USD
-0.42 USD
Jan 1, 2024
0.32 USD
-0.37 USD
-0.35 USD
Jan 1, 2025
1.83 USD
-1.77 USD
-1.71 USD
Jan 1, 2026 (e)
24.58 USD
10.82 USD
2.44 USD

Biomerica business model & stock analysis

Biomerica Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Biomerica Employees
Details
Date
Biomerica Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Biomerica Segments

Biomerica Revenue by Segment (1/2)

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Date
Clinical Lab
Physicians Office
Over The Counter
Over The Counte
Contract Manufacturing
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Biomerica Revenue by Segment (2/2)

  • 3 Years

  • 5 Years

  • Max

Clinical Lab
Physicians Office
OTC
Over-the-counter
Contract Manufacturing
Lab Supplies
Details
Date
Clinical Lab
Physicians Office
OTC
Over-the-counter
Contract Manufacturing
Lab Supplies
Jan 1, 2020
2.92 M USD
2.19 M USD
1.27 M USD
0.00 USD
305,760.00 USD
0.00 USD
Jan 1, 2021
3.08 M USD
2.80 M USD
0.00 USD
766,000.00 USD
552,000.00 USD
3,000.00 USD

Biomerica Revenue by Region

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

Asia
North America
Europe
Middle East
United States
South America
Other Foreign
Details
Date
Asia
North America
Europe
Middle East
United States
South America
Other Foreign
Jan 1, 2014
0.00 USD
1.30 M USD
0.00 USD
2.45 M USD
76,000.00 USD
1.26 M USD
19,000.00 USD
19,000.00 USD
Jan 1, 2015
0.00 USD
1.02 M USD
0.00 USD
2.72 M USD
143,000.00 USD
1.04 M USD
21,000.00 USD
24,000.00 USD
Jan 1, 2016
0.00 USD
1.73 M USD
0.00 USD
2.17 M USD
180,000.00 USD
995,000.00 USD
67,000.00 USD
1,000.00 USD
Jan 1, 2017
0.00 USD
2.41 M USD
0.00 USD
2.24 M USD
186,000.00 USD
874,000.00 USD
65,000.00 USD
17,000.00 USD
Jan 1, 2018
0.00 USD
2.51 M USD
0.00 USD
2.02 M USD
132,000.00 USD
685,000.00 USD
214,000.00 USD
4,000.00 USD
Jan 1, 2019
0.00 USD
2.51 M USD
0.00 USD
1.69 M USD
214,000.00 USD
523,000.00 USD
256,000.00 USD
0.00 USD
Jan 1, 2022
13.38 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
1.72 M USD
1.66 M USD
1.30 M USD
630,000.00 USD
0.00 USD
8,000.00 USD
0.00 USD

Biomerica Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Biomerica historical P/E ratio, EBIT multiple, and P/S ratio

Biomerica annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Biomerica shares outstanding

The number of shares of Biomerica was 2.91 M in 2025. This indicates how many shares Biomerica is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
9.82 M Stocks
Jan 1, 2020
11.76 M Stocks
Jan 1, 2021
12.59 M Stocks
Jan 1, 2022
13.46 M Stocks
Jan 1, 2023
16.82 M Stocks
Jan 1, 2024
17.12 M Stocks
Jan 1, 2025
2.91 M Stocks
Jan 1, 2026 (e)
2.91 M Stocks

Biomerica stock splits

In Biomerica's history, there have been no stock splits.

Current Biomerica forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
85.71 % (6)
Hold
14.29 % (1)
Sell
0.00 % (0)
12M Price Target
13.26
Last Price
1.58
Currency
USD
12M Return Potential
739.24 %
LTM Return
0 %

Biomerica Analyst Rating Actions

DateFirmActionRating
10/19/2020
Aegis Capital
Aegis Capital
MaintainedBuy
9/4/2020
Aegis Capital
Aegis Capital
MaintainedBuy
8/21/2020
Aegis Capital
Aegis Capital
MaintainedBuy
12/17/2018
B. Riley Securities
B. Riley Securities
MaintainedBuy
12/17/2018
B. Riley FBR
B. Riley FBR
MaintainedBuy

Biomerica Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/28/20230.04USD--USD-2023 Q4
4/12/20230.02USD--USD-2023 Q3
10/13/2022-0.02USD--USD-2023 Q1
9/9/2022-0.12USD-2.18 MUSD-2022 Q4
4/12/2022-0.10USD-2.94 MUSD-2022 Q3
1/12/2022-0.08USD-1.83 MUSD-2022 Q2
10/14/2021-0.12USD-1.93 MUSD-2022 Q1
8/27/2021-0.11USD-2.25 MUSD-2021 Q4
4/14/2021-0.08USD-1.44 MUSD-2021 Q3
1/14/2021-0.10USD-1.89 MUSD-2021 Q2

Biomerica shareholder structure

% Name
5.51765%
Irani (Zackary S)
Irani (Zackary S)
1.23487%
Barbieri (Allen)
Barbieri (Allen)
0.99752%
Emerson (Jane)
Emerson (Jane)
0.81232%
Lu (Gary)
Lu (Gary)
0.70364%
Moatazedi (David)
Moatazedi (David)
0.33113%
Chin (Eric)
Chin (Eric)

Biomerica Beneficial Ownership Filings (SEC 13D/G)

Free Float
89.8%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
10.95%
20-5873662
20-5873662
SEC ↗
8.81%
Granahan Investment Management LLC
Granahan Investment Management LLC
SEC ↗
7.70%
ROBERT J. McNULTY
ROBERT J. McNULTY
SEC ↗
7.70%
RIDGEROSE CAPITAL PARTNERS, LLC
RIDGEROSE CAPITAL PARTNERS, LLC
SEC ↗
7.50%
The BroadOak Fund, LLC
The BroadOak Fund, LLC
SEC ↗
7.37%
Wellington Trust Company, NA
Wellington Trust Company, NA
SEC ↗
5.70%
Wasatch Advisors LP 87-0319391
Wasatch Advisors LP 87-0319391
SEC ↗
5.70%
Joseph L. Rink
Joseph L. Rink
SEC ↗
5.46%
Palm Management (US) LLC
Palm Management (US) LLC
SEC ↗
5.46%
Palm Global Small Cap Master   Fund LP
Palm Global Small Cap Master Fund LP
SEC ↗

Biomerica Executives and Management Board

7 members · avg. age 57 · 14 % women

GL

Mr. Gary Lu (44)

Chief Financial Officer

385,636.00 USD

Management

ZI

Mr. Zackary Irani (58)

Chief Executive Officer, Director · since 1994

360,103.00 USD
AB

Mr. Allen Barbieri (66)

Executive Vice Chairperson of the Board and Corporate Secretary · since 1999

243,983.00 USD
SM

Mr. Scott Madel

Chief Commercial Officer

Board of Directors

DM

Mr. David Moatazedi (46)

Independent Director

157,822.00 USD
JE

Dr. Jane Emerson (69)

Independent Director

137,710.00 USD
EC

Mr. Eric Chin

Independent Director

Biomerica Supply Chain

Biomerica Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
1 companies
#NameTrend
1
TELCON RF PHARMACEUTICAL
Supplier·Customer·Electronic Equipment, Instruments & Components·KR
0.30
0.80
0.22
0.40
-0.15
0.57

Frequently asked questions about Biomerica

Analysts currently set an average price target of 13.26 USD for the Biomerica stock (median: 13.26 USD), implying +739.2 % versus the latest price. The consensus is based on 7 analyst ratings.

7 analysts currently rate the Biomerica stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Biomerica to generate revenue of 74.24 M USD and earnings per share of 2.53 USD.

Converted at the current exchange rate, the Biomerica share trades at 1.37 EUR (1.58 USD).

The Biomerica share (BMRA) is listed on 1 stock exchanges, including: NASDAQ (BMRA).

No history available for Biomerica.

The expected revenue of Biomerica is 74.24 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Biomerica is 7.36 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Biomerica is currently 0.62. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Biomerica stock.

The price-to-sales ratio (P/S) of Biomerica is currently 0.06. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Biomerica stock.

The Eulerpool Quality Score for Biomerica is 2/10.

The ISIN of Biomerica is US09061H4065. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Biomerica is 866251. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Biomerica is BMRA. The ticker symbol is used to trade Biomerica shares on the stock exchange.

Biomerica paid dividends every year for the past 0 years.

Biomerica is assigned to the 'Health' sector.

The dividends of Biomerica are distributed in USD.

All fundamentals and in-depth analysis of Biomerica

Our stock analysis for Biomerica stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biomerica. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.